Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06841172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 27 words
    • Publications: details revised at 9 of 9 entries
  2. Start date changed from estimate of Jul 1, 2025 to Jul 21, 2025v5
  3. Start date: Apr 15, 2025 to Jul 1, 2025
    • Primary completion date: Mar 15, 2027 to Jul 1, 2027
    • Study completion date: Mar 15, 2028 to Jul 1, 2028
    v4
  4. Start date: Mar 15, 2025 to Apr 15, 2025v3
  5. Primary completion date: Feb 24, 2027 to Mar 15, 2027v2 Show 4 more changesShow less
    • Study completion date: Feb 24, 2028 to Mar 15, 2028
    • Start date: Feb 24, 2025 to Mar 15, 2025
    • Interventions: Systemic therapy (Continuation of current first-line systemic therapy) (Drug), Systemic therapy (early switch to regorafenib) (Drug)… to Systemic therapy (Continuation of current first-line systemic therapy) (Drug), Systemic therapy (Early switch to second-line systemic…
    • Study description revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.
Trial Details
NCT Number NCT06841172
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions
(from sponsor)		 OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
Related terms Carcinoma, Hepatocellular
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov